Susanne Staer

Flybits to exhibit at Mobile World Congress 2013, officially launch Flybits LITE

February 21, 2013
Susanne Staer
Flybits

Flybits’ Context-Aware and Intelligent Mobility Solutions on exhibit Feb. 25 to 28, Canadian Pavilion, Stand 7F50, Booth 14

TORONTO, Canada (Feb. 14, 2013) – Flybits, a start-up company that develops context-aware and intelligent mobility solutions, today announced that they will be exhibiting at Mobile World Congress 2013 to launch a revolutionary mobile product called Flybits LITE.

Flybits LITE, an innovative Platform as a Service (PaaS), enables the quick creation and deployment of context-aware mobile computing applications for enterprises without the dependency of dedicated infrastructure. This unified and scalable platform, which provides personalized and relevant content to mobile users, will be officially launched and showcased throughout the Mobile World Congress event.

XLV Diagnostics Inc. awarded $500,000 to develop digital mammography technology

TORONTO, ON (Feb. 19, 2013) – XLV Diagnostics Inc., a start-up company working to commercialize a faster, cheaper and better digital mammography technology, has received a $500,000 investment from FedNor.

Over 600 million women living in developing countries have inadequate access to breast screening for early cancer detection. In the developed world, many radiology departments are replacing traditional film and screen systems with digital technologies. In both cases, better digital mammography technology promises to solve logistical challenges and save money.

XLV’s solution has the potential to provide image quality that equals or surpasses that which is currently in use, making images easy to analyze, manipulate and transfer much like digital photographs. It will also substantially decrease the cost of digital mammography machines.

FedDev Ontario awards Xagenic Inc. $990,000 through Investing in Business Innovation initiative

TORONTO, Feb. 19, 2013 — Xagenic Inc., a privately-held molecular diagnostics company, today announced that it will receive up to $990,000 in funding from the Government of Canada to support design and development of the first lab-free molecular diagnostic platform with a 20-minute time to result.

The Honourable Gary Goodyear, Minister of State for the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), made the announcement in the keynote speech at the Conference Board of Canada’s Business Innovation Summit 2013 in Toronto this morning.

BioDiaspora Founder Kamran Khan interviewed in Maclean’s Magazine

February 12, 2013
Susanne Staer
BlueDot

India’s Kumbh Mela, an annual mass Hindu pilgrimage of faith, is unlikely to create a disease outbreak that spreads beyond the country’s borders, Dr. Kamran Khan, founder of BioDiaspora, tells Maclean’s Magazine‘s Hannah Hoag in “As millions gather for Kumbh Mela, doctors are watching” (February 11, 2013).

Here’s an excerpt (emphasis ours):

Unlike the hajj or the Olympics, the Kumbh Mela is primarily a domestic event. While flights into Saudi Arabia spike to five times normal during the hajj, “with the Kumbh Mela, it’s marginal,” says Khan, “probably five to 10 per cent at some airports.”

To help stem disease outbreaks that do cross borders, such as the 2003 SARS outbreak in Toronto, Khan developed Bio.Diaspora, an online tool that shows how international travellers can spread infectious diseases. Khan is also working with another group of scientists—along with the U.S. Centers for Disease Control and Prevention (CDC)—to develop a tool called BioMosaic that maps census data, migration patterns and health status to identify countries where international travel may give rise to emerging disease.

MaRS Innovation awarded $15 million to further commercialize world-leading Canadian innovations

February 6, 2013
Susanne Staer
Awards

Networks of Centres of Excellence recognizes strength of partnership between MI and its 16 member institutions

TORONTO, February 5, 2013 — How do you make sure the brilliant ideas emerging from Toronto’s academic research community get the best possible chance to succeed?

MaRS Innovation (MI), created in 2008, bridges the chasm between these early-stage technologies and successful start-up companies and licensable technologies. By offering early-stage funding in tandem with hands-on management, mentorship and IP strategy protection, MI acts as a commercialization agent for its 16 member institutions.

This announcement was covered by TechVibes, Yonge Street Media and CanTech Letter.

The Networks of Centres of Excellence (NCE) has recognized the increasing strength of this novel partnership by awarding MI $14.95 million in funding through the Centres of Excellence for Commercialization and Research (CECR) program.

Raphael Hofstein gives guest lecture on biotechnology commercialization at Stanford

Dr. Raphael Hofstein, president and CEO of MaRS Innovation, delivered a guest lecture on February 1,2013 at the Revitalizing Medical BioTechnology Commercialization symposium, hosted by Stanford University‘s NIH Graduate Training Program in Biotechnology.

The one-day event brought academic, venture capital and industry thought leaders together to reflect on the challenges facing technology transfer processes across the biotech industry.

UTEST program: Giving U of T students a new way to become their own bosses

February 6, 2013
Susanne Staer
Media Coverage

The Varsity's coverage of the UTEST program — The Varsity’s coverage of the UTEST program. Photographed at the bottom left is **Will Walmsley**, founder of Whirlscape.

“There is a path somewhere between extended study and becoming an office worker,” wrote The Varsity‘s Angela Brock, in “Be Your Own Boss: Student entrepreneurs combine creativity and business to forge new career paths” (February 3, 2012). “As it turns out, there are plenty of opportunities for those looking to flex their entrepreneurial muscles without straying too far from the bosom of U of T.”

Brock’s article describes UTEST, the joint U of T-MaRS Innovation program that helps students, faculty and recent alumni commercialize software ideas.

It also profiles Will Walmsley, founder of Whirlscape, and Tyler Lu, co-founder of Granata Decision Systems, about their UTEST experience leading companies created through the program’s first cohort.

DLVR: Using personalized medicine and nature’s cellular toolkit to target cancer tumours

Every six weeks, MaRS Innovation’s marketing and communications manager writes a guest post for the MaRS Discovery District blog profiling MI’s activities or one of our start-up companies. This post coincided with World Cancer Day.

What if you could use a cancer tumour’s proteomic profile to make it easier to target and destroy?

Targeting specific proteins on the surface of individual tumours—or, more precisely, targeting a cell receptor that naturally allows substances to pass into a cell—would allow clinicians to more effectively deliver drugs designed to deactivate cancer-promoting genes within the tumour, while minimizing the addition of toxins to the patient’s body.

Personalized medicine research in Toronto also benefited from a recent $50 million donation to support Princess Margaret Hospital (part of the University Health Network). Read and watch the news announcement on BioTechnology Focus.

This is personalized medicine’s promise for cancer treatment: targeted therapies that stand a better chance of success, with reduced side effects, based on the unique profile of a patient’s tumour, either administered on their own or in combination with traditional chemotherapy.

University of Toronto Early-Stage Technology Program (UTEST) opens applications for second start-up company cohort

January 30, 2013
Susanne Staer
CoursePeer

Students, faculty and recent alumni with software ideas must apply by Feb. 22

Got a killer software-based idea? Are you passionate about turning that idea into a start-up company?

If you’re a current student, faculty member or recent graduate of the University of Toronto, consider applying to the University of Toronto Early-Stage Technology (UTEST) program.

Applications are now closed. Stay tuned for the third UTEST application call.

Created as a pilot in 2012 to help the U of T community bring their software-based ideas to market, UTEST is part of a growing ecosystem of incubators and commercialization support services.

UTEST accepts companies in the very earliest stages of idea generation— before they’re ready for traditional incubators — and awards each company up to $30,000 in start-up funds.

It also provides nascent software companies with office space in the MaRS Discovery District, mentoring and business strategy support.

“From a results standpoint, we couldn’t be more satisfied with first cohort of companies,” says Kurtis Scissons, co-director of UTEST at U of T. “In six months, they secured over $650,000 in follow-on funding. Each has filed solid patent protection and some are already gaining customer traction. They have also collectively created 21 highly-skilled jobs (HQPs).”

Update May 2013: Those figures now stand at $1.2 million and 29 jobs; most of the companies have secured customers.

OCE invests $250,000 in ScarX Therapeutics’ revolutionary anti-scarring medication

TORONTO, ON (Jan. 24, 2013) – ScarX Therapeutics, a start-up company commercializing a groundbreaking treatment to dramatically reduce post-operation scarring, is receiving a $250,000 investment from Ontario Centres of Excellence.

This story was covered in Yonge Street Media on January 30, 2013.

ScarX, a topical medication, emerged from Dr. Benjamin Alman‘s research. Alman, head of orthopedic surgery at the Hospital for Sick Children, is developing his invention in conjunction with MaRS Innovation.

Benjamin Alman, founder of ScarX Therapeutics. — **Dr. Benjamin Alman**, founder of ScarX Therapeutics. Photo courtesy of The Hospital for Sick Children.

Each year, doctors worldwide perform 240 million surgeries. Currently, no clinically-proven prescription therapeutic exists to reduce post-surgical scarring. Given this critical need for its technology, ScarX Therapeutics believes sales of the ScarX product could potentially reach into the billions of dollars.

“ScarX is a true game-changer when it comes to reducing the scarring associated with many surgeries,” said Dr. Tom Corr, president and CEO of Ontario Centres of Excellence. “Through our Market Readiness program, OCE is pleased to be supporting both the commercialization of this revolutionary research-based product and Ontario’s economy.”